William J. Link Phd - Jun 12, 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Jun 12, 2025
Transactions value $
$0
Form type
4
Date filed
6/16/2025, 04:03 PM
Previous filing
Jun 4, 2025
Next filing
Sep 10, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LINK WILLIAM J PHD Director C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Scott Sieckert, Attorney-in-Fact 2025-06-16 0001228684

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +3.35K +2% 170K Jun 13, 2025 Direct F1
holding TARS Common Stock 10.4K Jun 12, 2025 By Link Family Enterprise, LP F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +4.54K $0.00 4.54K Jun 12, 2025 Common Stock 4.54K $40.95 Direct F3
transaction TARS Restricted Stock Units Award $0 +2.95K $0.00 2.95K Jun 12, 2025 Common Stock 2.95K Direct F4, F5
transaction TARS Restricted Stock Units Options Exercise $0 -3.35K -100% $0.00 0 Jun 13, 2025 Common Stock 3.35K Direct F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2 The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.
F3 Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F4 Each RSU represents a contingent right to receive one share of the Company's common stock.
F5 RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F6 RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.